论文部分内容阅读
美国纽约消息:在抗菌药物的研究中,目前转向解决疾病持续这一复杂问题。加拿大一位获奖的研究人员在抗菌药物和化疗国际会议(ICAAC)上说,随着新一代药物及抗生素类新药的不断上市,疾病持续问题更为多见。而且将比以往更难解决。 Calgary大学微生物及传染病科LawrenceBryan医师说在过去20年左右,制药工业的成果是针对解决一惯的、高度的、单一的抗药机制问题。在此期间,克服这些抗药性机制已取得很大的成就。但总的说来,这些药物对解决久治不愈疾病的效果不是很好。在过去的5
NEW YORK, USA (Reuters Health) - In the study of antimicrobial agents, the current shift to solving the complex problem of disease persistence. An award-winning Canadian researcher at the International Conference on Antibacterials and Chemotherapeutics (ICAAC) said that the problem of disease persistence is more common with a new generation of drugs and new antibiotic drugs. And will be harder to solve than before. Lawrence Bryan, MD, of the Department of Microbiology and Infectious Diseases at Calgary University, said that over the past 20 years or so, the pharmaceutical industry has addressed the issue of settling a single, high, single mechanism of resistance. In the meantime, great achievements have been made in overcoming these resistance mechanisms. But in general, these drugs are not very effective in resolving drowned diseases. In the past 5